Serum testosterone, androstenedione and luteinizing hormone levels after short‐term medroxyprogesterone acetate treatment in women with polycystic ovarian disease

Leena Anttila, Pertti Koskinen, Risto Erkkola, Kerttu Irjala, Kristiina Ruutiainen

Research output: Contribution to journalArticlepeer-review

Abstract

Background. Medroxyprogesterone acetate (MPA) ‐treatment suppresses serum gonadotropin and androgen concentrations in women with polycystic ovarian disease (PCOD). This study ws designed to determine serum testosterone (T), androstenedione (A) and luteinizing hormone (LH) patterns in a group of oligomenorrheic PCOD patients after MPA‐treatment. Methods. The study group consisted of 11 women with ultrasonographically diagnosed PCOD. Blood samples were drawn in the morning in fasting conditions first during oligomenorrhea and then within one week after MPA‐induced bleeding. After that the sampling was repealed four times at one week intervals. Student's paired t‐test was used for statistical calculations. Results. The levels of T, A and LH decreased significantly after MPA‐treatment. During the follow‐up the T and A concentrations increased significantly till the third sampling week, after which no further increases were found. Conclusions. Our results show that T and A secretion return to levels characteristic of PCOD after discontinuation of MPA‐treatment within a few weeks in women with PCOD. 1994 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted

Original languageEnglish (US)
Pages (from-to)634-636
Number of pages3
JournalActa Obstetricia et Gynecologica Scandinavica
Volume73
Issue number8
DOIs
StatePublished - Sep 1994
Externally publishedYes

Keywords

  • androstenedione
  • luteinizing hormone
  • medroxyprogesterone acetate
  • polycystic ovarian disease
  • testosterone

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Serum testosterone, androstenedione and luteinizing hormone levels after short‐term medroxyprogesterone acetate treatment in women with polycystic ovarian disease'. Together they form a unique fingerprint.

Cite this